GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Danaher Corp (NYSE:DHR) » Definitions » FCF Margin %
中文

Danaher (Danaher) FCF Margin %

: 45.19% (As of Dec. 2023)
View and export this data going back to 1986. Start your Free Trial

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Danaher's Free Cash Flow for the three months ended in Dec. 2023 was $1,217 Mil. Danaher's Revenue for the three months ended in Dec. 2023 was $2,693 Mil. Therefore, Danaher's FCF Margin % for the quarter that ended in Dec. 2023 was 45.19%.

As of today, Danaher's current FCF Yield % is 3.08%.

The historical rank and industry rank for Danaher's FCF Margin % or its related term are showing as below:

DHR' s FCF Margin % Range Over the Past 10 Years
Min: 17.37   Med: 23.5   Max: 28.7
Current: 24.2


During the past 13 years, the highest FCF Margin % of Danaher was 28.70%. The lowest was 17.37%. And the median was 23.50%.

DHR's FCF Margin % is ranked better than
92.86% of 224 companies
in the Medical Diagnostics & Research industry
Industry Median: -10.51 vs DHR: 24.20


Danaher FCF Margin % Historical Data

The historical data trend for Danaher's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Danaher Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.51 24.31 28.70 27.78 24.20

Danaher Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.43 23.33 22.15 19.02 45.19

Competitive Comparison

For the Diagnostics & Research subindustry, Danaher's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Danaher FCF Margin % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Danaher's FCF Margin % falls into.



Danaher FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Danaher's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=5781/23890
=24.20 %

Danaher's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=1217/2693
=45.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Danaher FCF Margin % Related Terms

Thank you for viewing the detailed overview of Danaher's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Danaher (Danaher) Business Description

Address
2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, USA, 20037-1701
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in two segments--life sciences and diagnostics--after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
Executives
Jose-carlos Gutierrez-ramos officer: SVP, Chief Scientific Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Linda Filler director 2200 PENNSYLVANIA AVE NW, SUITE 800W, WASHINGTON DC 20037
Daniel Raskas officer: VP-Corporate Development 2099 PENNSYLVANIA AVENUE, NORTHWEST, WASHINGTON DC 20006
Teri List director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Joakim Weidemanis officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Walter G Lohr director DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Georgeann Couchara officer: SVP, Human Resources 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Raymond C Stevens director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Matthew Mcgrew officer: EVP & Chief Financial Officer 2200 PENNSYLVANIA AVENUE, NW, SUITE 800 W, WASHINGTON DC 20010
Jennifer Honeycutt officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Alan G Spoon director 1150 15TH ST NW, WASHINGTON DC 20071
Rainer Blair officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Feroz Dewan director C/O ARENA HOLDINGS MANAGEMENT LLC, 119 FIFTH AVENUE - 8TH FLOOR, NEW YORK NY 10003
Mitchell P Rales director, officer: Chairman of Exec. Committee 11790 GLEN ROAD, POTOMAC MD 20854
Brian W Ellis officer: Senior Vice President - GC 2200 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20037

Danaher (Danaher) Headlines

From GuruFocus

Q1 2021 Danaher Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Danaher Corp at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Danaher Corp Annual Shareholders Meeting Transcript

By GuruFocus Research 01-22-2024

Q1 2022 Danaher Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Danaher Corp Investor and Analyst Meeting Transcript

By GuruFocus Research 01-22-2024